What does this research mean for the field?

Advancing nuclear theranostics beyond current efficacy limits requires shifting from incremental tracer optimization to biologically informed therapies, combination strategies, and enhanced diagnostic phenotyping. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.ESTABLISHES_NEW_DIRECTION.

What question did this study set out to answer?

To critically examine translational bottlenecks in nuclear theranostics and evaluate strategies for shifting from incremental tracer optimization toward biologically informed therapies.

August 27, 2026npj ImagingOpen Access

Nuclear theranostics at a crossroads:from tracer optimization to biologically informed therapy

View Full Paper

Ask AI

Bookmark

Authors

ALAlexandra LitvinenkoUniversity Hospital of Lausanne HKHélène KochUniversity Hospital of Lausanne GCGianluca CorsaniciUniversity Hospital of Lausanne

Discussion

Member takes

Implication

Review reveals limits of tracer optimization in nuclear theranostics, highlighting biologically informed combinations and diagnostic phenotyping to improve therapeutic index.

Key Points

To critically examine translational bottlenecks in nuclear theranostics and evaluate strategies for shifting from incremental tracer optimization toward biologically informed therapies.
Evaluated molecular engineering strategies, including plasma protein binding, metabolic stabilization, multimerization, covalent target ligation, and alternative radionuclides.
Assessed radiobiological mechanisms, interactions within the tumor microenvironment, dosimetry principles, and combination regimens involving immune checkpoint and PARP inhibitors.
Identified that conventional tracer optimization faces diminishing returns due to heterogeneous target expression, dose-limiting toxicity, and empirical dosing protocols.
Demonstrated that advancing the therapeutic index requires combining radioligands with targeted radiosensitizers and utilizing diagnostic imaging for functional tumor phenotyping.

Cite This Study

Litvinenko et al. (2026) studied this question.

synapsesocial.com/papers/6a8fea0110c91c1e92622002 https://doi.org/10.1038/s44303-026-00189-0

View Full Paper

Ask AI

Bookmark

Implication

Review reveals limits of tracer optimization in nuclear theranostics, highlighting biologically informed combinations and diagnostic phenotyping to improve therapeutic index.

Nuclear theranostics at a crossroads:from tracer optimization to biologically informed therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Nuclear theranostics at a crossroads:from tracer optimization to biologically informed therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider